US Pharma MarketingCoya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen neuroinflammation, through a pivotal stage of development in ALS. Dr Arun Swaminathan tells Salong Debbarma how COYA 302’s FDA fast track status is shaping Coya’s next steps, from accelerating ALSTARS enrolment to aligning earlier with regulators on a path to clinically meaningful benefit. Coya Therapeutics CEO Dr Arun Swaminathan. Credit: LinkedIn. As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore…
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen neuroinflammation, through a pivotal stage of development in ALS.
Source: Pharmaceutical Technology